UNSPSC 51401513: Nitrazepam

This classification denotes a benzodiazepine with the molecular formula C15H11N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9CLV70W7HS, chemically known as 2,3-dihydro-7-nitro-5-phenyl-1h-1,4-benzodiazepin-2-on but generally known as nitrazepam, which bears US NIH Compound Identifier 4506. European Medicines Agency schedules Nitrazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09318MIG.

UNSPSC 51401513 Nitrazepam is a Commodity code that should index pharmaceutical products, but the single recent state-local opportunity posted under it — Seminole County, Florida's IFB60459723LAS — solicits Naloxone and Safe Drug Deactivation Systems, not Nitrazepam. The mismatch suggests either a coding error by the issuing body or a broader pharmaceutical and harm-reduction supply categorization that does not align with the specific drug name in the code's title. The Seminole County procurement itself is clear: the county seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, delivered quarterly to the Seminole County Community Health Building in Sanford, Florida, with all shipping and delivery costs included in vendor bids. The contract carries a two-year initial term with an optional one-year renewal, requires drug-free workplace certification and E-Verify compliance, and mandates workers' compensation, commercial general liability, and professional liability insurance. Bidders must submit electronic bids through the county's e-Procurement Portal on a fixed-fee basis with unit costs per line item.

This code shows minimal recent activity under its stated scope — only one opportunity has posted, and that opportunity does not directly align with Nitrazepam procurement. Seminole County, Florida, issued the IFB with a response deadline of July 26, 2023 (though the posting date shown is June 30, 2026, creating a temporal inconsistency in the source record). Without additional recent solicitations matching the Nitrazepam code or broader harm-reduction drug procurement patterns across other state and local jurisdictions, the code does not surface as an active procurement vehicle. Vendors pursuing opioid antagonists or pharmaceutical harm-reduction supplies should verify how state and local bodies are coding these procurements, as this code may not reliably index opportunities in that category.